Our mouse studies should provide experimental evidence that will form the basis of a paradigm regarding the functioning of Cisd2 in the development of NAFLD and NASH, and should also help the development of therapeutic strategies aimed at treating NAFLD and NASH. The gene discussed is CISD2; the disease is metabolic dysfunction-associated steatohepatitis.